资本财富规划公司增加了其Teva制药公司的持有量,使2019年Q4的股份增加了8.8%。 Capital Wealth Planning increased its Teva Pharmaceutical holdings, boosting shares by 8.8% in Q4 2019.

资本财富规划有限公司将其在Teva制药工业的股份在2019年Q4增加了8.8%,现在拥有246 601股,价值543.35万美元。 Capital Wealth Planning LLC boosted its holdings in Teva Pharmaceutical Industries by 8.8% in Q4 2019, now owning 246,601 shares worth $5.435 million. Teva的股票54.05%由机构投资者和对冲基金所有。 Teva's stock is owned 54.05% by institutional investors and hedge funds. 该公司报告,Q4 2019为0.70 EPS,击打分析师的估计数为0.01美元。 The company reported $0.70 EPS for Q4 2019, beating analysts' estimates by $0.01. 分析师给了Teva一个“机动购买”评级,平均目标价格为23.57美元。 Analysts give Teva a "Moderate Buy" rating with an average target price of $23.57. Teva侧重于开发和分销通用、专门和生物制药产品。 Teva focuses on developing and distributing generic, specialty, and biopharmaceutical products.